Otros
Recent advancement in drug development of nitro(NO2)-heterocyclic compounds as lead scaffolds for the treatment of Mycobacterium tuberculosis
Fecha
2022-01-01Registro en:
Drug Development Research.
1098-2299
0272-4391
10.1002/ddr.21921
2-s2.0-85124003111
Autor
University of Mississippi Medical Center (UMMC)
Universidade Estadual Paulista (UNESP)
Institución
Resumen
Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis (Mtb). It was responsible for approximately 1.4 million deaths worldwide in 2019. The lack of new drugs to treat drug-resistant strains is a principal factor for the slow rise in TB infections. Our aim is to aid the development of new TB treatments by describing improvements (last decade, 2011–2021) to nitro(NO2)-based compounds that have shown activity or pharmacological properties (e.g., anti-proliferative, anti-kinetoplastid) against Mtb. For all compounds, we have included final correlations of minimum inhibitory concentrations against Mtb (H37Rv).